| Drug Name |
Carmustine |
| Drug ID |
BADD_D00371 |
| Description |
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) |
| Indications and Usage |
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01AD01 |
| DrugBank ID |
DB00262
|
| KEGG ID |
D00254
|
| MeSH ID |
D002330
|
| PubChem ID |
2578
|
| TTD Drug ID |
D01OXI
|
| NDC Product Code |
54879-036; 43598-628; 70710-1525; 70860-223; 0781-3474; 50137-0686; 57821-002; 14593-823; 16729-545; 23155-790; 70121-1482; 76339-121; 50683-0017; 54893-0055; 68475-503; 57884-0032; 16729-548; 23155-649; 55718-139; 59651-168; 24338-050; 58621-002; 59981-034; 23155-261; 71288-126 |
| UNII |
U68WG3173Y
|
| Synonyms |
Carmustine | BCNU | N,N'-Bis(2-Chloroethyl)-N-Nitrosourea | FIVB | 1,3-Bis(2-Chloroethyl)-1-Nitrosourea | BiCNU | Nitrumon |
